Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
3.800
-0.110 (-2.82%)
Dec 31, 2025, 12:40 PM EST - Market open
Company Description
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc.
| Country | United States |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Joseph Tucker |
Contact Details
Address: 245 First Street, Riverview II Cambridge, Massachusetts 02142 United States | |
| Website | enveric.com |
Stock Details
| Ticker Symbol | ENVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 890821 |
| CUSIP Number | 29405E505 |
| ISIN Number | US29405E5050 |
| Employer ID | 95-4484725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer and Director |
| Kevin M. Coveney CPA | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2025 | EFFECT | Notice of Effectiveness |
| Dec 23, 2025 | D | Notice of Exempt Offering of Securities |
| Dec 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 22, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 17, 2025 | SCHEDULE 13G | Filing |
| Dec 12, 2025 | 8-K | Current Report |
| Dec 11, 2025 | 8-K | Current Report |
| Dec 10, 2025 | SCHEDULE 13G/A | Filing |
| Dec 10, 2025 | SCHEDULE 13G/A | Filing |
| Dec 10, 2025 | 424B3 | Prospectus |